Navigation Links
Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
Date:4/8/2008

- Agreement includes upfront, milestone and royalty payments on future

sales -

TORONTO, April 8 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. ("Lorus") (TSX: LOR; AMEX: LRP), a biopharmaceutical company dedicated to the research and development of pharmaceutical products and technologies for the management of cancer, announced today that its subsidiary GeneSense Technologies, Inc. ("GeneSense") has signed an exclusive multinational license agreement with Zor Pharmaceuticals LLC formed as a subsidiary of Zoticon Bioventures Inc. ("Zoticon"), a research-driven biopharmaceutical group, to further develop and commercialize Virulizin(R) for human therapeutic applications. The initial clinical development of Virulizin(R) under the agreement will be in advanced pancreatic cancer.

Under the terms of the agreement, GeneSense will be entitled to receive payments in excess of US$10 million upon achievement of various milestone events and royalties that vary from 10-20% depending on achieving of sales of Virulizin(R) and subject to certain other adjustments. In addition, a wholly owned subsidiary of Lorus, Pharma Immune Inc. ("Pharma Immune") will receive 25% of the initial equity in Zor Pharmaceuticals. Pharma Immune's equity will not be subject to dilution on the first US$5 million of financing in Zor Pharmaceuticals. Thereafter, Pharma Immune has, at its option, a right to participate in any additional financings to maintain its ownership level. In addition, GeneSense has entered into a Service Agreement with Zor Pharmaceuticals to assist in the transfer of knowledge and establish a strong foundation for moving forward with the development program for Virulizin.

Zor Pharmaceuticals will be responsible for the cost of all the clinical development, regulatory submissions and commercialization of Virulizin(R) in North and South America and Europe. GeneSense will retain rights in all other countries, including Jap
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 1, 2014 AACC, a global scientific and ... medicine, unveiled an updated brand identity today that reflects ... the changing healthcare environment and continue to do what ... patients get the care they need. ... play an essential role in saving lives and making ...
(Date:8/1/2014)... CHICAGO , Aug. 1, 2014 The  ... increasing the number and success rate of early-stage life ... today that it has awarded 15 grants to help ... AdvaMed 2014: The MedTech Conference   in ... leading MedTech conference in North America ...
(Date:8/1/2014)... , Aug. 1, 2014 Research and ... "Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market ... http://photos.prnewswire.com/prnh/20130307/600769 Single Nucleotide Polymorphism ... variations of SNPs in the genome of various species. ... SNP genotyping and analysis technology can analyze thousands of ...
(Date:8/1/2014)... 2014 BCC Research ( http://www.bccresearch.com ) ... TECHNOLOGIES AND GLOBAL MARKETS , that the global market ... grow to nearly $38.8 billion by 2018, with a ... aptamer delivery category, the fastest moving segment of the ... The field of RNAi therapeutics has shown tremendous growth ...
Breaking Biology Technology:AACC Debuts Refreshed Brand Identity 2iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 2iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 3iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 4Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 3
... fields and tiny iron-bearing particles to drive healthy cells ... in animals, may lead to a new method of ... organs in people. , The study team, led by ... of Pediatric Cardiology at The Childrens Hospital of Philadelphia, ...
... ALTO, Calif., Jan. 7 Telik, Inc. (Nasdaq: ... overview at the,26th Annual JPMorgan Healthcare Conference in San ... Pacific time (10:30 a.m. Eastern,time). A live and archived ... website, http://www.telik.com ., Telik, Inc. of Palo ...
... Potential Blockbuster Product for High Risk Cardiovascular ... ... Calif., Jan. 7 ,Genzyme Corp. (Nasdaq: GENZ ) and Isis ... a major strategic alliance in which,Genzyme will develop and commercialize mipomersen, ...
Cached Biology Technology:Researchers use magnetism to target cells to animal arteries 2Researchers use magnetism to target cells to animal arteries 3Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 2Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 3Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 4Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 5Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 6Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 7
(Date:7/31/2014)... found to be a key gene responsible for hearing in ... cells of the inner ear that contracts and expands rapidly ... phonograph horn, amplify sound waves to make hearing more sensitivity. ... advanced online edition of Molecular Biology and Evolution , ... independently evolved to play a critical role in the ultrasonic ...
(Date:7/31/2014)... Fla. --- By tracing nearly 3,000 genes to ... University of Florida scientists have created an extensive ... use large-scale, next-generation DNA sequencing. , Among ... closely related to small moths than to large ... butterflies evolved. The study also found that some ...
(Date:7/31/2014)... DARIEN, IL Researchers who studied 100 twin pairs have ... function normally on less than six hours of sleep per ... resistance to the effects of sleep deprivation. , Results show ... BHLHE41 gene had an average nightly sleep duration of ... than the non-carrier twin, who slept for about six hours ...
Breaking Biology News(10 mins):UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3Study of twins discovers gene mutation linked to short sleep duration 2
... 2011)Regular exercise has proven benefits in preventing and ... tough to meet the American Diabetes Association guidelines of ... A new study, conducted by researchers at McMaster University, ... a small proof-of-principle study in eight type 2 diabetes ...
... How to manage waste has become one of the ... of electrical and electronic equipment that is designed, manufactured and ... and at times highly toxic. Up to 1,200 companies working ... to 10% of their recycling costs thanks to this new ...
... plant growth enhancers are becoming increasingly sought-after. Many ... with limited research capabilities, have not been tested ... effectiveness been documented by scientific data. Researchers from ... effect of Tea Seed Powder (TSP), a saponin-rich ...
Cached Biology News:Exercising harder -- and shorter -- can help Type 2 diabetes 2Exercising harder -- and shorter -- can help Type 2 diabetes 31,200 recycling sector companies will save up to 10 percent thanks to a new system developed by Tecnalia 2Plant growth affected by tea seed powder 2
A univariate (peak height or area) quantitative multi-component analysis package....
... The micro 1 is a dramatic breakthrough ... from 1mL with 10nL resolution, the micro 1 ... benchtop dispenser. And, the micro 1 never needs ... , Touch Screen programming on an LCD Display ...
... microscopes offer all of the features of ... Equipped with Koehler illumination, a centerable condenser ... B3 is the workhorse of Motic's range ... the need for re-focusing following a change ...
... Dye Primer Manual Cycle Sequencing Kit is ... primers and high-resolution fluorescence scanners. Sequencing reactions ... slab gel electrophoresis and scanning of the ... The kit components have been optimized ...
Biology Products: